# MCE ®

### **Product** Data Sheet

## **Bretylium tosylate**

Cat. No.: HY-12961A CAS No.: 61-75-6

Molecular Weight: 414.36

Target: Adrenergic Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: 4°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (241.34 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4134 mL	12.0668 mL	24.1336 mL
	5 mM	0.4827 mL	2.4134 mL	4.8267 mL
	10 mM	0.2413 mL	1.2067 mL	2.4134 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.03 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: 2.5 mg/mL (6.03 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (6.03 mM); Clear solution; Need ultrasonic


#### **BIOLOGICAL ACTIVITY**

Description

Bretylium (tosylate) is an inhibitor of the presynaptic release of vasoconstrictor neurotransmitters. It is the sympathetic nerve and adrenergic ganglion blocking agent .(1) Bretylium tosylate inhibits adrenergic function presynaptically only after an initial release in neurotransmitter substance.(2) The reference for administration dose is 15 mg/kg (I.P).

#### **REFERENCES**

[1]. McGinn R et al. Adenosine receptor inhibition attenuates the suppression of postexercise cutaneous blood flow. J Physiol. 2014 Jun 15;592(12):2667-78.



Page 2 of 2 www.MedChemExpress.com